8-KItem 1.01 · Material AgreementItem 2.03 · Financial ObligationItem 3.02 · Unregistered Equity SalesItem 8.01 · Other EventsItem 9.01 · Financial Statements
Moderna Prices Upsized $2.6 Billion Convertible Notes Offering
Filed with the SEC on · Summarized by InvestorsBot
Moderna priced $2.6 billion of 0.00% convertible senior notes due March 1, 2032, up from the initially proposed $2.0 billion, with closing expected September 1, 2026. The company expects approximately $2.563 billion in net proceeds, including about $285 million for capped-call transactions, with the remainder available for general purposes such as oncology investment and debt repayment; the notes initially convert at about $210.58 per share, a 47.5% premium to Moderna’s August 27 closing price.